Transforming healthcare sustainably
Life-changing innovation is only meaningful if it reaches those who need it. We put access at the core of our business and consider it a key part of our commitment to improving patient outcomes. We partner with stakeholders at global, country and community levels to enable access to innovative healthcare, no matter where people live.
![[Potrait] Christoph Franz](https://assets.roche.com/f/176343/1514x1514/74c82ee2df/ar22-digital-letters-cf.jpg/m/320x320/filters:format(webp):quality(90)/)
“It has been a great honour for me to work for this unique and excellent company. With Severin Schwan and Thomas Schinecker, Roche is being led into the future by a strong and highly experienced team.”
Dr Christoph Franz
Chairman
“There is no doubt that, throughout his tenure, our outgoing Chairman has strongly influenced Roche’s strategic development. Thank you very much, Christoph Franz!”
André Hoffmann
Vice-Chairman
:quality(90)/)
:quality(90)/)
“The development and delivery of pioneering medicines and diagnostics is at the heart of our mission. I am particularly pleased that we brought two new medicines to patients: for certain severe eye diseases and for a form of blood cancer.”
Dr Severin Schwan
CEO
Key highlights2022
+2%*
Roche Group sales:
CHF 63.3 billion
+2%
Pharmaceuticals Division sales:
CHF 45.6 billion
+3%
Diagnostics Division sales:
CHF 17.7 billion
+3%
Core investments in
research and development:
CHF 14.1 billion
+3%
Core operating profit:
CHF 22.2 billion
+2%
Dividend proposal:
CHF 9.50
*Unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates (CER; average rates 2021) and all total figures quoted are reported in CHF.
United States
9
Actemra/RoActemra (two indications)
Cotellic
Lunsumio
Tecentriq
Evrysdi
Vabysmo (two indications)
Xofluza
Europe
5
Lunsumio
Polivy
Tecentriq
Vabysmo (two indications)
China
4
Actemra/RoActemra
Rozlytrek (two indications)
Tecentriq
Japan – Chugai
9
Actemra/RoActemra
Gazyva/Gazyvaro
Hemlibra
Perjeta + Herceptin
Polivy
Tecentriq
MabThera/Rituxan
Vabysmo (two indications)
Molecular Lab
2 new platforms
2 new tests
1 other
Pathology Lab
1 new platform
9 new tests
3 new digital solutions
1 other
Core Lab
4 new platforms
12 new tests
1 new digital solution
Point of Care
1 new test
Diabetes Care
1 new digital solution
Roche Information Solutions
4 new digital solutions
>3.2 million
people were on Roche patient support programmes, a 14% increase from 2021
Ranked 10th
worldwide in the Access to Medicine Index
>8 million
HIV-positive patients were able to have their viral load monitored through the Global Access Program to check for treatment efficacy
13 cities
We continue to work with City Cancer Challenge, who are active in 13 cities worldwide reaching an estimated 59.6 million people
100,000 people
will be screened for diabetes over the next two years in Meru, Kenya, through the Mwanga access project
29 billion
tests conducted with Roche Diagnostics products
36.7%
women in executive positions
15.5%
under-represented nationalities in executive positions*
>80
diversity networks and chapters around the globe
4 strategic D&I pillars
Global D&I strategy focuses on four pillars: patient, people, culture, and society
No significant difference
in pay between men and women in similar jobs as our organisation-wide analysis confirmed
Roche CEO signs pledge
with the Valuable 500committing support for disability inclusion.
*Includes individuals from countries in Asia, Latin America, Eastern Europe, Middle East and Africa
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)